Octreotide in the management of treatment-related diarrhoea

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 1, 1996, Pages 11-15

  Baillie Johnson, Hugo R ^a  

^a NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Diarrhoea; Octreotide; Radiation enteritis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; METHOTREXATE; OCTREOTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; DIARRHEA; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; INJECTION PAIN; LIVER DYSFUNCTION; MORBIDITY; PRIORITY JOURNAL; RADIATION ENTEROPATHY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOM;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DIARRHEA; ENTERITIS; GRAFT VS HOST DISEASE; HUMANS; NEOPLASMS; OCTREOTIDE; RADIATION INJURIES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS;

EID: 0030024269     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199601001-00003     Document Type: Review

References (43)

1. Delaney JP, Bonsack ME, Felemovicius I. Misoprostol in the intestinal lumen protects against radiation injury of the mucosa of the small bowel. Radiat Res 1994; 137: 405-409.
2. Delaney JP, Bonsack ME, Felemovicius I. Lumenal route for intestinal radioprotection. Am J Surg 1993; 166: 492-501.
3. Fedorak RN, Allen SL. Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats: a limited systemic effect. Dig Dis Sci 1989; 34: 567-572.
4. Lechner P, Cesnik H. Ahdominopelvic omentopexy: preparatory procedure for radiotherapy in rectal cancer. Dis Colon Rectum 1992; 35: 1157-1160.
5. Yeoh EK, Horowitz M, Russo A, et al. Gastrointestinal function in chronic radiation enteritis: effects of loperamide-N-oxide. Gut 1993; 34: 476-482.
6. Yeoh E, Horowitz M, Russo A, et al. Effect of pelvic-irradiation on gastrointestinal function: a prospective longitudinal study. Am J Med 1993; 95: 397-406.
7. Shulkes A. Gastrointestinal hormones: from basic-science to a clinical perspective. Aust NZ J Surg 1990; 60: 575-578.
8. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 3: 658-702.
9. McKenna KJ, Ligato S, Kauffman GLJ, et al. Epidermal growth factor enhances intestinal mitotic activity and DNA content after acute abdominal radiation. Surgery 1994; 115: 626-632.
10. Baughan CA, Canney PA, Buchanan RB, Pickering RM. A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol R Coll Radiol 1993; 5: 19-24.
11. Smid WM, Dullaart RP. Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth J Med 1992; 40: 5-6.
12. Buchanan KD, Collins JS, Varghese A, et al. Sandostatin and the Belfast experience. Digestion 1990; 45 (suppl 1): 11-14.
13. Dean AP, Reed WD. Diarrhoea: an unrecognised hazard of coeliac plexus block. Aust NZ J Med 1991; 21: 47-48.
14. Mackie CR, Jenkins SA, Hartley MN. Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide. Br J Surg 1991; 78: 1338-1343.
15. Collignon A, Jeantils V, Cruaud P, et al. Prevalence of Clostridium difficile and toxin A in feces of HIV infected patients [in French]. Pathol Biol Paris 1993; 41: 415-420.
16. Girard PM, Goldschmidt E, Vittecoq D, et al. Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS 1992; 6: 715-718.
17. Nielsen H, Daugaard G, Tvede M, et al. High prevalence of Clostridium difficile diarrhoea during intensive chemotherapy for disseminated germ cell cancer. Br J Cancer 1992; 66: 666-667.
18. Fiasse R, Pauwels S, Rahier J, et al. Use of octreotide in the treatment of digestive neuroendocrine tumours: seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma. Acta Gastroenterol Belg 1993; 56: 3-4.
19. Creutzfeldt W, Bartsch HH, Jacubaschke U, et al. Treatment of gastrointestinal endocrine tumours with interferon alpha and octreotide. Acta Oncol 1991; 30: 529-535.
20. Verhelst J, De Longueville M, Ongena P, et al. Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 1994; 62: 83-88.
21. Tenny CM, Przepiorka D, Shapiro S, et al. Octreotide for transplant related diarrhoea [abstract 1160]. Proc Am Soc Clin Oncol 1991; 10: 329.
22. Bianco JA, Higano C, Singer J, et al. The somatostatin analog octreotide in the management of the secretory diarrhoea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194-1195.
23. Ely P, Dunitz J, Rogosheske J. Use of a somatostatin analog, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991; 90: 707-710.
24. Cascinu S, Fedeli A, Fedeli SL, et al. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 2-3.
25. Cascinu S, Fedeli A, Fedeli SL, et al. Control of chemotherapy-induced diarrhoea with octreotide. Oncology 1994; 51: 70-73.
26. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhoea in patients with colorectal carcinoma. Cancer 1993; 72: 1543-1546.
27. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhoea following chemotherapy. Anti-Cancer Drugs 1993; 4: 443-445.
28. Bisset WM, Jenkins H, Booth I, Smith V, Milla PJ. The effect of somatostatin on small intestinal transport in intractable diarrhoea of infancy. J Pediatr Gastroenterol Nutr 1993; 17: 169-175.
29. Burroughs AK, Malagelada R. Potential indications for octreotide in gastroenterology: summary of workshop. Digestion 1993; 54 (suppl 1): 59-67.
30. Linkesch M, Kuzmits R, Geyer G. Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b. Wien Klin Wochenschr 1989; 101: 455-457.
31. Mahler C, Verhelst J, De Longueville M, Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 1990; 33: 261-269.
32. Manfredi R, Vezzadini P, Costigliola P, Ricchi E, Fanti MP, Chiodo F. Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea: effects of treatment with octreotide. AIDS 1993; 7: 223-226.
33. Misra SC. Endocrine diarrhoeas; current concepts. Trop Gastroenterol 1990; 11: 87-98.
34. Moroni M, Esposito R, Cernuschi M, Franzetti F, Carosi GP, Fiori GP. Treatment of AIDS-related refractory diarrhoea with octreotide. Digestion 1993; 54 (suppl 1): 30.
35. Mourad FH, Gorard D, Thillainayagam AV, Colin Jones D, Farthing MJ. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut 1992; 33: 1578-1580.
36. Neef B, Horing E, von Gaisberg U. Successful treatment of a life-threatening ileostomy diarrhea with the somatostatin analog octreotide. Dtsch Med Wochenschr 1994; 119: 869-874.
37. Nightingale JM, Walker ER, Burnham WR, Farthing MJ, Lennard Jones JE. Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Ther 1989; 3: 367-373.
38. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30: 503-507.
39. Parmar H, Charlton CD, Phillips RH, et al. Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer. Clin Exp Metastasis 1992; 10: 3-11.
40. Philippe J. APUDomas: acute complications and their medical management. Baillieres Clin Endocrinol Metab 1992; 6: 217-228.
41. Romeu J, Miro JM, Sirera G, et al. Efficacy of octreotide in the management of chronic diarrhoea in AIDS. AIDS 1991; 5: 1495-1499.
42. Verhelst J, De Longueville M, Ongena P, Denis L, Mahler C. Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 1994; 62: 83-88.
43. Woods HF, Bax ND, Ainsworth I. Abdominal carcinoid tumours in Sheffield. Digestion 1990; 45 (suppl 1): 17-22.